GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Long-Term Debt

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Long-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Long-Term Debt?

Infant Bacterial Therapeutics AB's Long-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

Infant Bacterial Therapeutics AB Long-Term Debt Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Long-Term Debt Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Infant Bacterial Therapeutics AB  (GREY:IFTBF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Infant Bacterial Therapeutics AB Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Long-Term Debt
Comparable Companies
OSTO:FLUO OSTO:HNSA OSTO:BINV OSTO:XSPRAY OSTO:EGTX OSTO:VICO OSTO:ONCO OSTO:DMYD B OSTO:CANTA OSTO:XBRANE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IBT B:Sweden 9IB:Germany
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Website
https://www.ibtherapeutics.com
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines